Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?

Core Viewpoint - Johnson & Johnson's recent earnings report shows strong performance, with shares increasing by approximately 13% since the last report, outperforming the S&P 500. The company beat earnings and sales estimates for Q4 2025, indicating positive momentum leading into 2026 [1][2]. Financial Performance - Q4 2025 earnings were $2.46 per share, exceeding the Zacks Consensus Estimate of $2.43, and reflecting a 20.6% increase year-over-year. Reported earnings, including special items, were $2.10 per share, up 48.9% year-over-year [3]. - Sales reached $24.56 billion, surpassing the Zacks Consensus Estimate of $24.12 billion, with a 9.1% increase from the previous year. This growth was driven by a 7.1% operational increase and a 2.0% positive currency impact [4]. Segment Performance - The Innovative Medicines segment saw sales rise 10.0% year-over-year to $15.76 billion, beating estimates. Key products like Darzalex and Tremfya contributed significantly to this growth, although Stelara's loss of exclusivity negatively impacted growth by 1110 basis points [6][7][8]. - The MedTech segment reported sales of $8.8 billion, up 7.5% year-over-year, driven by strong performance in Cardiovascular, Surgery, and Vision. This segment also exceeded estimates [17][18]. Future Guidance - For 2026, Johnson & Johnson expects sales between $100.0 billion and $101.0 billion, indicating growth of 6.2%-7.2%. Adjusted earnings per share are projected to be in the range of $11.43-$11.63, with operational growth expected to be 5.9%-7.9% [24][25]. - The company anticipates accelerated growth in both the Innovative Medicine and MedTech segments, despite challenges such as the loss of exclusivity for Stelara and potential generic competition for other products [27][28][29]. Market Sentiment - Recent estimates for Johnson & Johnson have trended downward, indicating a shift in market sentiment. The company currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the near term [30][32].